Myokines, which are recently identified cytokines secreted by skeletal muscle in response to stimulation, are crucial for the maintenance of liver function. Fulminant hepatitis (FH) is a life-threatening pathological condition with severe hepatic dysfunction. In this study, we investigated the role of meteorin-like (METRNL), a new myokine, in the pathogenesis of FH. We compared serum samples and liver tissues from FH patients and healthy controls and found that hepatic and serum METRNL levels were significantly increased in FH patients, and serum METRNL levels were related to disease severity in FH patients. We then established a concanavalin A-induced FH model in METRNL-overexpressing and control mice. We found that hepatic METRNL levels in FH mice were significantly increased, and METRNL in the liver was mainly derived from macrophages. In the cultured mouse macrophage line (RAW264.7 cells) and mouse primary peritoneal macrophages (PMs), METRNL overexpression significantly inhibited the release of the proinflammatory cytokines TNF and IL-1β. In METRNL-overexpressing mice, concanavalin A-induced liver injury was significantly ameliorated. Moreover, METRNL overexpression significantly reduced chemokine-dependent inflammatory cell infiltration into the liver. METRNL overexpression also suppressed liver CD4+ T cell differentiation into Th 1 cells and inhibited the secretion of Th 1 cytokines. Taken together, these data suggest that METRNL overexpression effectively ameliorates FH. Therefore, METRNL may serve as a potential biomarker and therapeutic target for FH.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
The dataset (excluding personal identifiers) will be available to proper academic parties upon request from the corresponding author in accordance with the data sharing policies of Shanghai Jiao Tong University School of Medicine.
Sass DA, Shakil AO. Fulminant hepatic failure. Liver Transpl. 2005;11:594–605.
Antoniades CG, Berry PA, Wendon JA, Vergani D. The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol. 2008;49:845–61.
Stravitz RT, Lee WM. Acute liver failure. Lancet. 2019;394:869–81.
European Association for the Study of the Liver. Electronic address eee, Clinical practice guidelines p, Wendon J, Panel M, Cordoba J, Dhawan A, et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66:1047–81.
Moon JH, Koo BK, Kim W. Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey. J Cachexia Sarcopenia Muscle. 2021;12:964–72.
Li T, Xu M, Kong M, Song W, Duan Z, Chen Y. Use of skeletal muscle index as a predictor of short-term mortality in patients with acute-on-chronic liver failure. Sci Rep. 2021;11:12593.
Praktiknjo M, Clees C, Pigliacelli A, Fischer S, Jansen C, Lehmann J, et al. Sarcopenia is associated with development of acute-on-chronic liver failure in decompensated liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. Clin Transl Gastroenterol. 2019;10:e00025.
Bay ML, Pedersen BK. Muscle-organ crosstalk: focus on immunometabolism. Front Physiol. 2020;11:567881.
Whitham M, Febbraio MA. The ever-expanding myokinome: discovery challenges and therapeutic implications. Nat Rev Drug Discov. 2016;15:719–29.
Monserrat-Mesquida M, Quetglas-Llabres M, Abbate M, Montemayor S, Mascaro CM, Casares M, et al. Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants (Basel). 2020;9:759.
Ruiz-Margain A, Pohlmann A, Ryan P, Schierwagen R, Chi-Cervera LA, Jansen C, et al. Fibroblast growth factor 21 is an early predictor of acute-on-chronic liver failure in critically ill patients with cirrhosis. Liver Transpl. 2018;24:595–605.
Zheng SL, Li ZY, Song J, Liu JM, Miao CY. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin. 2016;37:571–9.
Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157:1279–91.
Bridgewood C, Russell T, Weedon H, Baboolal T, Watad A, Sharif K, et al. The novel cytokine Metrnl/IL-41 is elevated in Psoriatic Arthritis synovium and inducible from both entheseal and synovial fibroblasts. Clin Immunol. 2019;208:108253.
Ushach I, Burkhardt AM, Martinez C, Hevezi PA, Gerber PA, Buhren BA, et al. METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages. Clin Immunol. 2015;156:119–27.
Baht GS, Bareja A, Lee DE, Rao RR, Huang R, Huebner JL, et al. Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism. Nat Metab. 2020;2:278–89.
Xu L, Cai Y, Wang Y, Xu C. Meteorin-Like (METRNL) attenuates myocardial ischemia/reperfusion injury-induced cardiomyocytes apoptosis by alleviating endoplasmic reticulum stress via activation of AMPK-PAK2 signaling in H9C2 cells. Med Sci Monit. 2020;26:e924564.
Reboll MR, Klede S, Taft MH, Cai CL, Field LJ, Lavine KJ, et al. Meteorin-like promotes heart repair through endothelial KIT receptor tyrosine kinase. Science. 2022;376:1343–7.
Pan H, Huang W, Wang Z, Ren F, Luo L, Zhou J, et al. The ACE2-Ang-(17)-Mas axis modulates M1/M2 macrophage polarization to relieve CLP-induced inflammation via TLR4-mediated NF-кb, Cyrillicb and MAPK pathways. J Inflamm Res. 2021;14:2045–60.
Wang HX, Liu M, Weng SY, Li JJ, Xie C, He HL, et al. Immune mechanisms of Concanavalin A model of autoimmune hepatitis. World J Gastroenterol. 2012;18:119–25.
Fan H, Fan J, Chen S, Chen Y, Gao H, Shan L, et al. Prognostic significance of end-stage liver diseases, respiratory tract infection, and chronic kidney diseases in symptomatic acute hepatitis E. Front Cell Infect Microbiol. 2020;10:593674.
Miao ZW, Hu WJ, Li ZY, Miao CY. Involvement of the secreted protein Metrnl in human diseases. Acta Pharmacol Sin. 2020;41:1525–30.
Gholamrezayi A, Mohamadinarab M, Rahbarinejad P, Fallah S, Barez SR, Setayesh L, et al. Characterization of the serum levels of Meteorin-like in patients with inflammatory bowel disease and its association with inflammatory cytokines. Lipids Health Dis. 2020;19:230.
Li M, Sun X, Zhao J, Xia L, Li J, Xu M, et al. CCL5 deficiency promotes liver repair by improving inflammation resolution and liver regeneration through M2 macrophage polarization. Cell Mol Immunol. 2020;17:753–64.
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.
Neiswender JV, Kortum RL, Bourque C, Kasheta M, Zon LI, Morrison DK, et al. KIT suppresses BRAF(V600E)-mutant melanoma by attenuating oncogenic RAS/MAPK signaling. Cancer Res. 2017;77:5820–30.
Hsueh YS, Chang HH, Shan YS, Sun HS, Fletcher JA, Li CF, et al. Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors. Oncogene. 2019;38:6550–65.
Ushach I, Arrevillaga-Boni G, Heller GN, Pone E, Hernandez-Ruiz M, Catalan-Dibene J, et al. Meteorin-like/Meteorin-beta is a novel immunoregulatory cytokine associated with inflammation. J Immunol. 2018;201:3669–76.
Liu ZX, Ji HH, Yao MP, Wang L, Wang Y, Zhou P, et al. Serum Metrnl is associated with the presence and severity of coronary artery disease. J Cell Mol Med. 2019;23:271–80.
Zuo L, Ge S, Ge Y, Li J, Zhu B, Zhang Z, et al. The adipokine metrnl ameliorates chronic colitis in Il-10-/- mice by attenuating mesenteric adipose tissue lesions during spontaneous colitis. J Crohns Colitis. 2019;13:931–41.
This study was funded by the Natural Science Foundation of Shanghai (20ZR1433500), the Major Project of National Thirteenth Five-year Plan (2017ZX09304016), and the National Natural Science Foundation of China (8210030899).
The authors declare no competing interests.
Consent to participate
Written consent was obtained from each subject.
The study was approved by the Human Ethics Committee, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Du, Yn., Teng, Jm., Zhou, Th. et al. Meteorin-like protein overexpression ameliorates fulminant hepatitis in mice by inhibiting chemokine-dependent immune cell infiltration. Acta Pharmacol Sin (2023). https://doi.org/10.1038/s41401-022-01049-4
- fulminant hepatitis
- kupffer cells
- Th 1 cells